Inhibitor Therapeutics INTI

Inhibitor Therapeutics, Inc. is a pharmaceutical development company focused on creating and commercializing innovative therapeutics based on already approved active pharmaceutical ingredients that possess patent protected methods of use or delivery. The company targets patients with certain cancers and noncancerous proliferation disorders, and it also explores acquiring or licensing pre clinical and clinical stage therapies that repurpose approved drugs to address unmet medical needs. Its current primary program utilizes the antifungal drug itraconazole to develop treatments for basal cell carcinoma nevus syndrome, prostate cancer and lung cancer in the United States. Inhibitor Therapeutics, Inc. has built intellectual property and knowhow related to the use of itraconazole in oncology indications. On December 12, 2023 the company entered into an exclusive license agreement with Johns Hopkins University granting worldwide rights to a patent covering angiogenesis inhibitors for the treatment of prostate cancer, basal cell carcinoma including basal cell carcinoma nevus syndrome and lung cancer.

Inhibitor Therapeutics, Inc. does not yet generate product revenue; its business model anticipates income from the future commercialization of its therapeutic candidates, from milestone payments associated with licensing agreements, and from royalties on net sales of any approved products. Under the license agreement the company paid an upfront fee of $40,000 and is obligated to pay mid single digit percentage royalties on net sales, with a higher percentage for sales that have exclusivity in the United States due solely to the patent rights. Minimum annual royalty payments are set at $10,000 for each of the first two years, $15,000 for the third year, $50,000 for the fourth year and each year thereafter until the first commercial sale of a licensed product, after which the minimum annual royalty rises to $150,000 per year. The agreement also provides for a low double digit percentage of any consideration received from sublicensees and for development related milestone payments totaling $3 million upon achievement of predefined milestones such as a successful Phase 3 trial, commercialization and FDA approval of a licensed product.

Inhibitor Therapeutics, Inc. occupies a niche within the broader oncology and rare drug repurposing sector, competing with other biopharma firms that develop cancer therapies but differentiating itself by leveraging the established safety profiles of approved drugs and securing patent protected methods of use. The company believes this approach reduces development risk and time to market relative to novel molecular entities. In May 2024 Inhibitor Therapeutics, Inc. requested a Type B pre IND meeting with the FDA to obtain feedback on the regulatory plan for using itraconazole to treat basal cell carcinoma tumors in basal cell carcinoma nevus syndrome patients. Although the initial meeting with the Division of Dermatology was cancelled, the company engaged external experts and worked with the FDA to ensure input from the Division of Oncology would be included. Inhibitor Therapeutics, Inc. has engaged Avior Bio to develop a novel formulation of itraconazole; Avior has completed formulation development and will conduct a pharmacokinetic crossover study comparing the generic formulation with the formulation used in the Phase IIb study to support a new pre IND and a future new drug application. The company has also submitted an application to the FDA to participate in the Rare Disease Endpoint Advancement pilot program. As of September 30, 2025 Inhibitor Therapeutics, Inc. reported cash on hand of approximately $3 million, which management states is sufficient to sustain operations, continue the FDA process for the basal cell carcinoma nevus syndrome product without additional clinical trials and explore other drug development opportunities for the foreseeable future.

The company intends to serve patients diagnosed with basal cell carcinoma nevus syndrome, prostate cancer and lung cancer, as well as the hospitals, oncology clinics and healthcare providers that treat these conditions. Inhibitor Therapeutics, Inc. expects that successful commercialization of its itraconazole based therapies will generate revenue from both direct product sales and from licensing or partnership arrangements with larger pharmaceutical companies. The firm’s customer base therefore includes individual patients, medical practitioners, treatment centers and potential corporate collaborators interested in oncology and rare disease therapeutics.